Last checked at 29 Jun 2020 07:00
Blocklisting Six Monthly Return
London: Monday, June 29, 2020: Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
1. | Name of applicant:
| Hutchison China MediTech Limited | ||
2. | Name of scheme:
| (a) | Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 ("2005 HCML Share Option Scheme")
| |
(b) | Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 ("2015 HCML Share Option Scheme")
| |||
3. | Period of return:
| From December 29, 2019 to June 28, 2020
| ||
4. | Balance under scheme from previous return:
| (a) | 2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US$0.1 each
| |
(b) | 2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each
| |||
5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
| (a) | 2005 HCML Share Option Scheme: Nil
| |
(b) | 2015 HCML Share Option Scheme: Nil
| |||
6. | Number of securities issued/allotted under scheme during period:
| (a) | 2005 HCML Share Option Scheme: Nil
| |
(b) | 2015 HCML Share Option Scheme: Nil
| |||
7. | Balance under scheme not yet issued/allotted at end of the period:
| (a) | 2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US$0.1 each
| |
(b) | 2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each
| |||
8. | Number and class of securities originally listed and the date of admission:
| 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) | ||
9. | Total number of securities in issue at the end of the period:
| 690,574,765 ordinary shares of US$0.1 each | ||
Name of contact:
| Christian Hogg | |||
Address of contact:
| Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong
| |||
Telephone number of contact: | +852 2121 8200 | |||
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries | |
Mark Lee, Senior Vice President | +852 2121 8200 |
Annie Cheng, Vice President | +1 (973) 567 3786 |
Media Enquiries | |
Americas - Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) bmiles@troutgroup.com |
Europe - Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com |
Asia - Joseph Chi Lo / Zhou Yi, Brunswick | +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com |
Nominated Advisor | |
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |